Actinic Keratosis Treatment Market (By Therapy: Topical, Surgery, Photodynamic Therapy; By Drug Class: Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers, Others; By End-use: Hospitals, Private Clinics, Homecare, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

Published Date : Oct 2021 | No. of Pages : 150+ Pages | Category : Healthcare


Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Actinic Keratosis Treatment Market, By Therapy

7.1.  Actinic Keratosis Treatment Market, by Therapy, 2021-2030

7.1.1.    Topical

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Surgery

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Photodynamic Therapy

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Actinic Keratosis Treatment Market, By Drug Class

8.1.  Actinic Keratosis Treatment Market, by Drug Class, 2021-2030

8.1.1.    Nucleoside Metabolic Inhibitor

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    NSAIDs

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Immune Response Modifiers

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Photoenhancers

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Actinic Keratosis Treatment Market, By End User

9.1.  Actinic Keratosis Treatment Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Private Clinics

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Homecare

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Others

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Actinic Keratosis Treatment Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.1.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.2.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.3.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.4.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.5.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Sun Pharmaceutical Industries Ltd.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Novartis AG

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              GALDERMA

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Hill Dermaceuticals, Inc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Viatris Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Mylan N.V.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Bausch Health Companies, Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              LEO Pharma A/S

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Almirall, S.A.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Biofrontera AG

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           3M

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms

Featured Research Reports

  • Featured Research Reports

    U.S. Virtual Visits Market (By Service Type: Cold & Flu management, Allergies, Urgent Care, Preventive Care, Chronic Care Management, Behavioural Health ; By Commercial Plan Type: Small Group, Self-Funded/ASO Group Plans, Medicaid, Medicare, By Age Group, By Gender)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    Next-Generation Sequencing Services Market (By Service Type: Human Genome Sequencing, Gene Regulation Services; By Workflow: Pre-sequencing, Sequencing, Data Analysis; By End-use)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    Pediatric Clinical Trials Market (By Phase: Phase II, IV; By Study Design: Treatment, Observational Studies; By Therapeutic Areas: Mental Health Disorders, Oncology)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    Medical Digital Imaging Systems Market (By Type: X-ray, MRI, Ultrasound, CT, Nuclear Imaging; By Technology: 2D, 3D/4D) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    U.S. Pharmacy Benefit Management Market (By Business Model: Standalone, Health Insurance Providers, Retail Pharmacy; By End Use: Commercial, Federal) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...